BioPharma Resources

Drug Trial Radar · NCT04613596

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 626 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

626

Planned (sponsor's estimate)

Start

Dec 2, 2020

Primary completion

Oct 31, 2028

Study completion Oct 31, 2029

Sponsor

Lead sponsor
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.

Conditions

  • Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer

Interventions

  • AdagrasibDrug

    Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)

  • AdagrasibDrug

    Adagrasib 600 mg BID monotherapy (Cohort 1b)

  • AdagrasibDrug

    adagrasib 400 mg BID in combination with pembrolizumab

  • AdagrasibDrug

    Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W

  • PembrolizumabDrug

    Pembrolizumab 200 mg IV Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.Time frame: 22 months
  2. Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumabTime frame: 36 months

Locations

776 sites in 47 countries. Site status is shown where the registry gives one.

  • Local Institution - 007-556-A

    Goodyear, Arizona · Not yet recruiting

  • USOR - Arizona Oncology - Prescott Valley

    Prescott Valley, Arizona · Recruiting

  • Local Institution - 007-568-A

    Safford, Arizona · Not yet recruiting

  • Local Institution - 007-568-B

    Safford, Arizona · Not yet recruiting

  • Local Institution - 007-568-C

    Safford, Arizona · Not yet recruiting

  • Local Institution - 007-568-D

    Safford, Arizona · Not yet recruiting

  • Local Institution - 007-568-E

    Safford, Arizona · Not yet recruiting

  • Arizona Clinical Research Center

    Tucson, Arizona · Recruiting

  • Highlands Oncology Group - Springdale

    Springdale, Arkansas · Recruiting

  • Providence - Saint Joseph Home Health - Anaheim

    Anaheim, California · Recruiting

  • The Oncology Institute of Hope and Innovation - Corporate Office

    Cerritos, California · Recruiting

  • Local Institution - 007-777

    Fountain Valley, California · Not yet recruiting

  • Local Institution - 007-778

    Laguna Hills, California · Not yet recruiting

  • Local Institution - 007-898-B

    Long Beach, California · Not yet recruiting

  • MemorialCare - Long Beach Medical Center

    Long Beach, California · Recruiting

  • TRIO - Cancer & Blood Specialty Clinic - Los Alamitos

    Los Alamitos, California · Recruiting

  • Local Institution - 007-579

    Los Angeles, California · Withdrawn

  • Local Institution - Unk045

    Rancho Mirage, California · Active not recruiting

  • San Francisco Veterans Affairs Medical Center

    San Francisco, California · Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Local Institution - 007-898-C

    Santa Ana, California · Not yet recruiting

  • Providence Medical Group - Santa Rosa

    Santa Rosa, California · Recruiting

  • Stockton Hematology Oncology Medical Group (SHOMG) - Stockton (Suite B)

    Stockton, California · Recruiting

  • Local Institution - 007-898-A

    Whittier, California · Not yet recruiting

  • Local Institution - 007-872-H

    Aurora, Colorado · Not yet recruiting

  • Local Institution - 007-872-D

    Boulder, Colorado · Not yet recruiting

  • Local Institution - 007-872-L

    Centennial, Colorado · Not yet recruiting

  • Local Institution - 007-872-C

    Colorado Springs, Colorado · Not yet recruiting

  • Local Institution - 007-872-K

    Colorado Springs, Colorado · Not yet recruiting

  • Local Institution - 007-872-E

    Denver, Colorado · Not yet recruiting

  • Local Institution - 007-872-I

    Denver, Colorado · Not yet recruiting

  • Local Institution - 007-872-A

    Lakewood, Colorado · Not yet recruiting

  • Local Institution - 007-872-J

    Littleton, Colorado · Not yet recruiting

  • USOR - Rocky Mountain Cancer Centers - Lone Tree

    Lone Tree, Colorado · Recruiting

  • Local Institution - 007-872-G

    Longmont, Colorado · Not yet recruiting

  • Local Institution - 007-872-B

    Pueblo, Colorado · Not yet recruiting

  • Local Institution - 007-872-F

    Thornton, Colorado · Not yet recruiting

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut · Recruiting

  • Local Institution - 007-5476

    Washington D.C., District of Columbia · Not yet recruiting

  • GenesisCare USA

    Aventura, Florida · Recruiting

Showing 40 of 776 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.